Priya Jain, Pathophysiology of Hypertension: Treatment, Diagnosis, Risk and Etiology, ASIO Journal of Experimental Pharmacology & Clinical Research (ASIO-JEPCR), 2016, 1(1): 08-15.
ARTICLE TYPE: REVIEW
dids no.: 03.2016-35559215,
dids Link: http://dids.info/didslink/03.2016-44696291/
Hypertension basically does not show any major symptoms initially, but persistent hypertension over time is a major risk factor for hypertensive heart disease, stroke, coronary artery disease, peripheral artery disease, aortic aneurysm, and chronic kidney disease. Hypertension is further classified as either primary hypertension or secondary hypertension. Most of the cases, about 90–95% of cases are categorized as primary hypertension, defined as high blood pressure with no noticeable underlying cause. The remaining 5–10% of cases are categorized as secondary hypertension, defined as hypertension due to an restricted cause, such as chronic kidney disease, narrowing of the aorta or kidney arteries, or an endocrine disorder such as excess cortisol, aldosterone, or catecholamine. The simply way to know whether you have high blood pressure is to get it measured. The medical doctor will measure your blood pressure with an instrument called sphygmomanometer. Earlier the normal blood pressure reading was approximately 120/80 mm Hg, but as per the WHO guideline now a day it is considered as 130/90 mm Hg. There are several types of drugs used to treat high blood pressure, like Beta-blockers, Angiotensin-converting enzyme inhibitors, Angiotensin II receptor blockers (ARBs), Calcium channel blockers, Alpha-blockers, Diuretics, Alpha-agonists and Renin inhibitors etc.
Key words: Hypertension, treatment, diagnosis, risk, etiology
- Roccella EJ. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, American Journal of Obstetrics & Gynecology, 2000, 183 (1), pp. S1–S22.
- Maynard SE, Min JY, Merchan J. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia,” The Journal of Clinical Investigation, 2003, 111 (5), pp. 649–658.
- Arati G, Di Rienzo M, Ulian L, Santucciu C, Girard A, Elghozi J-L, Mancia G. Clinical relevance of blood pressure variability. J Hypertens. 1998, 16(suppl 3): S25–S33.
- Oint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997, 157: 2413–2446.
- Etrella RJ. How effective is exercise training for the treatment of hypertension? Clin J Sport Med. 1998, 8: 224–231.
- Kaplan NM. Systemic Hypertension: Treatment. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2011, chap 46.
- Victor RG. Systemic hypertension: Mechanisms and diagnosis. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2011, chap 45.
- Oh KT, Moinfar N. Ophthalmic manifestations of hypertension. Medscape Reference: Drugs, Diseases & Procedures. http://emedicine.medscape.com/article/1201779
- Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke
- Isles C. Hypertensive emergencies. In: Swales J, ed. Text Book of Hypertension. Oxford: Blackwell Scientific Publications, 1994, 1233.
- Lifton RP. Molecular genetics of human blood pressure variation. Science. 1996, 272: 676–680.
- Tripathi KD. Essential of medical pharmacology, Jaypee Brothers M edical Publishers (P) LTD, 2013, pg no. 556-574.
- Braghetta P. Overlapping, complementary and site-specific expression pattern of genes of the EMILIN/Multimerin family. Matrix biology : journal of the International Society for Matrix Biology, 2004, 22(7): p. 549-56.
- Colombatti A. The EMILIN protein family. Matrix biology : journal of the International Society for Matrix Biology, 2000, 19(4): p. 289-301.
- Zanetti M. EMILIN-1 deficiency induces elastogenesis and vascular cell defects. Molecular and cellular biology, 2004. 24(2): p. 638-50.
- Danussi C., et al., Emilin1 deficiency causes structural and functional defects of lymphatic vasculature. Molecular and cellular biology, 2008. 28(12): p. 4026-39.
- Doliana R. Structure, chromosomal localization, and promoter analysis of the human elastin microfibril interfase located protein (EMILIN) gene. The Journal of biological chemistry, 2000, 275(2): p. 785-92.